{"id":"W2084415993","doi":"10.1097/jto.0b013e318220c93e","title":"Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Adverse effect; Lung cancer; Progression-free survival; Clinical endpoint; Internal medicine; Nausea; Surgery; Phases of clinical research; Urology; Gastroenterology; Oncology; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001117123,0.001768651,0.002142082,0.0004500056,0.0004403216,0.001039221,0.000796171,0.001406802,0.005194733],"category_scores_gemma":[0.0007045201,0.000572072,0.001412085,0.0003369817,0.0008213079,0.000999206,0.0003862259,0.00368396,0.001397085],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001149624,"about_ca_system_score_gemma":0.001279904,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001455263,"about_ca_topic_score_gemma":0.004282745,"domain_scores_codex":[0.9996946,0.0001384176,0.000009522367,0.00004927127,0.00002158474,0.00008661376],"domain_scores_gemma":[0.9996207,0.00006405458,0.00004901652,0.00002627534,0.00002054862,0.0002194601],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8118377,0.02687237,0.00362811,0.0007347184,0.001373954,0.0002890521,0.0002068528,0.003315222,0.03100095,0.0005456518,0.0114051,0.1087903],"study_design_scores_gemma":[0.8505142,0.1351924,0.006185615,0.00003024889,0.0003243866,0.0002478107,0.00005244454,0.001400758,0.002007547,0.0003343501,0.003682938,0.00002734715],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9863441,0.003290536,0.0005057899,0.00217756,0.000482564,0.001471969,0.001865473,0.0002141997,0.003647794],"genre_scores_gemma":[0.9811802,0.002565458,0.001682873,0.002094661,0.0003383977,0.002013599,0.003902297,0.00006090508,0.00616166],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005194733,"threshold_uncertainty_score":0.01737809,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02273317214820727,"score_gpt":0.434747771304466,"score_spread":0.4120145991562588,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}